Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Rigel Pharmaceuticals (RIGL)

Rigel Pharmaceuticals (RIGL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer PR Newswire - Thu Aug 13, 7:05AM CDT

VEPPANU is the first and only FDA-approved PROTAC and has the potential to become an important new treatment option for adult patients with 2L+ ER+/HER2-, ESR1-mutated mBC

RIGL : 46.34 (-1.11%)
Rigel: Q2 Earnings Snapshot AP - Tue Aug 4, 3:08PM CDT

Rigel: Q2 Earnings Snapshot

RIGL : 46.34 (-1.11%)
Rigel Reports Second Quarter 2026 Financial Results PR Newswire - Tue Aug 4, 3:01PM CDT

SOUTH SAN FRANCISCO, Calif. , Aug. 4, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today...

RIGL : 46.34 (-1.11%)
Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results PR Newswire - Tue Jul 28, 7:05AM CDT

SOUTH SAN FRANCISCO, Calif. , July 28, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its second quarter 2026 financial results after market...

RIGL : 46.34 (-1.11%)
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) PR Newswire - Tue Jul 7, 7:05AM CDT

SOUTH SAN FRANCISCO, Calif. , July 7, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc....

RIGL : 46.34 (-1.11%)
Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer PR Newswire - Wed Jul 1, 7:05AM CDT

SOUTH SAN FRANCISCO, Calif. , July 1, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today...

RIGL : 46.34 (-1.11%)
Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant) PR Newswire - Tue Jun 16, 3:01PM CDT

SOUTH SAN FRANCISCO, Calif. , June 16, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today...

RIGL : 46.34 (-1.11%)
Rigel to Present at the Jefferies Global Healthcare Conference PR Newswire - Wed May 27, 7:05AM CDT

SOUTH SAN FRANCISCO, Calif. , May 27, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today...

RIGL : 46.34 (-1.11%)
Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress PR Newswire - Thu May 21, 4:17PM CDT

SOUTH SAN FRANCISCO, Calif. , May 21, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today...

RIGL : 46.34 (-1.11%)
Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference PR Newswire - Thu May 14, 7:05AM CDT

SOUTH SAN FRANCISCO, Calif. , May 14, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today...

RIGL : 46.34 (-1.11%)

Barchart Exclusives

Sandisk Stock Could Nearly Double to $3,000, According to Wall Street Barchart - 34 minutes ago
SNDK stock has a $3,000 high price target. These catalysts could make it possible. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.